Download This Paper
Preprints with The Lancet is a collaboration between The Lancet Group of journals and SSRN to facilitate the open sharing of preprints for early engagement, community comment, and collaboration. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early-stage research papers that have not been peer-reviewed. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. The findings should not be used for clinical or public health decision-making or presented without highlighting these facts. For more information, please see the FAQs.
Tiotropium as a Treatment Option for Severe Uncontrolled Asthma in Preschool Patients
24 Pages Posted: 29 Jul 2020
More...Abstract
Background: Toddlers with asthma suffer disproportionally more than school-aged children from exacerbations with emergency visits and hospital admissions despite inhaled corticosteroid (ICS) treatment. A recent trial for children ≤5 years showed tolerability of tiotropium and potential to reduce asthma-related events.
Methods: We conducted a retrospective analysis of electronic outpatient records (2017‒2019) of children <6 years treated with ICS plus long-acting β2-agonists (LABAs) plus tiotropium as add-on for uncontrolled severe asthma. Primary endpoint was comparison of systemic corticosteroid (SCS) prescriptions 6 months before and after ICS/LABA/tiotropium start. Secondary endpoints included physician visits, hospitalisations and antibiotic prescriptions. We compared outcomes with children without asthma matched for age, sex and screening date.
Findings: Compared with a mean 2.42 (95% CI 1.75, 3.36) SCS courses per patient within 6 months prior to ICS/LABA/tiotropium, 0.74 (95% CI 0.25, 1.08) SCS courses per patient were prescribed within 6 months after starting ICS/LABA/tiotropium (P<0.001). Physician visits dropped from 9.23 (95% CI 7.15, 12.72) to 5.76 (95% CI 3.10, 7.70) per patient (P<0.01). Nineteen hospitalisations in nine patients were recorded 6 months before ICS/LABA/tiotropium compared with one hospitalisation after (P<0.01). A mean 1.79 antibiotic courses (95% CI 1.22, 2.23) per patient were prescribed before ICS/LABA/tiotropium compared with 0.74 (95% CI 0.22, 1.00) after ICS/LABA/tiotropium (P<0.001). Hospitalisation rates for patients at observation end were not statistically different from healthy controls before/after matching.
Interpretation: Tiotropium is a potential add-on for preschool patients with uncontrolled severe asthma; however, larger confirmatory studies are needed.
Funding Statement: Medical writing assistance, provided by Kristina Standeven PhD, is funded by Boehringer Ingelheim.
Declaration of Interests: SZ reports grants and personal fees from bene-Arzneimittel GmbH, grants from ALK Arzneimittel, personal fees from Novartis GmbH, Boehringer Ingelheim, Lofarma GmbH, IMS HEALTH GmbH & Co. OHG, GSK, Stallergen, Procter and Gamble, Allergopharma GmbH, AstraZeneca, Sanofi/Pasteur, and Aimmune outside the submitted work.
Ethics Approval Statement: Ethics approval was obtained from the ethics committee of the J.W. Goethe University in Frankfurt (application number 149/19).
Keywords: pre-school asthma; uncontrolled asthma; tiotropium; triple tratment
Suggested Citation: Suggested Citation